982 related articles for article (PubMed ID: 17063113)
1. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
2. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.
Rijkers AP; Valkema R; Duivenvoorden HJ; van Eijck CH
Eur J Surg Oncol; 2014 Jul; 40(7):794-804. PubMed ID: 24755095
[TBL] [Abstract][Full Text] [Related]
6. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer.
Yoshioka M; Sato T; Furuya T; Shibata S; Andoh H; Asanuma Y; Hatazawa J; Shimosegawa E; Koyama K; Yamamoto Y
J Gastroenterol; 2004 Jan; 39(1):50-5. PubMed ID: 14767734
[TBL] [Abstract][Full Text] [Related]
7. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
[TBL] [Abstract][Full Text] [Related]
8. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
9. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.
Chang JS; Choi SH; Lee Y; Kim KH; Park JY; Song SY; Cho A; Yun M; Lee JD; Seong J
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):126-33. PubMed ID: 25015206
[TBL] [Abstract][Full Text] [Related]
11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
12. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
[TBL] [Abstract][Full Text] [Related]
13. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pancreatic carcinoma with FDG PET.
Jadvar H; Fischman AJ
Abdom Imaging; 2001; 26(3):254-9. PubMed ID: 11429948
[TBL] [Abstract][Full Text] [Related]
16. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
17. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
[TBL] [Abstract][Full Text] [Related]
18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
19. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
[TBL] [Abstract][Full Text] [Related]
20. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
